Dassault Systèmes extends cardiovascular collaboration with FDA
Dassault Systèmes has extended its collaboration with the U.S. Food and Drug Administration for another five years. The 3DExperience platform will be used to develop a new digital tool in a bid to enable more efficient regulatory review of cardiovascular and medical devices.
Researchers hope the process will increase industry innovation and pave the way for an efficient path for patients to access safe, effective new treatments for heart disease.
Claire Biot, vice president, life sciences industry, Dassault Systèmes, said: “Our collaboration with the FDA underscores the relevance and sustainability of digital twin experiences created with the 3DExperience platform to test devices and drugs in scientific and medical innovation. Enriching technology already well established in regulated industries such as aerospace and automotive, virtual patients support the complex development of therapies for the heart, brain and more by eliminating traditional cost and time bottlenecks. With this new review process, Dassault Systèmes and the FDA can be partners in the transformative impact of the virtual world on industrial innovation, new treatments and the patient experience.”
This second phase of their ongoing collaboration supports the 21st Century Cures Act, using virtual patients based on computational modelling and simulation to improve efficiency of clinical trials for new device designs. A project with the Living Heart simulated 3D heart model will examine the use of heart simulation as a source of digital evidence for new cardiovascular device approvals. This includes an in silico clinical trial aimed to reduce animal testing or the number of patients required while still ensuring safety and efficacy of the device is demonstrated. The new digital process is intended to be more efficient and less expensive than current ones – whose delays and costs can impede patient access to novel treatments – without losing rigor or confidence in a device’s safety and efficacy.
The FDA has publicly recognised the public health benefits offered by modelling and simulation, and the potential for in silico clinical trials to safely advance medical products more efficiently, from preclinical studies through clinical trials to market.
Tina Morrison, deputy director in the Division of Applied Mechanics, Office of Science and Engineering Labs, Centre for Devices and Radiological Health, FDA said: “Modelling and simulation can help to inform clinical trial designs, support evidence of effectiveness, identify the most relevant patients to study, and assess product safety. In some cases, in silico clinical trials have already been shown to produce similar results as human clinical trials. The FDA continues to encourage research to facilitate the introduction of safe and effective therapeutic solutions.”